Advertisement

Cytokines in multiple sclerosis cerebrospinal fluid and serum

  • P. Gallo
  • B. Tavolato

Abstract

Under normal conditions, cytokines are not readily detected in biological fluids, such as serum and cerebrospinal fluid (CSF), because they have a very short lifetime, act mainly as autocrine/paracrine growth/immunomodulating factors, and are absorbed instantly at the tissue/cell target level by high affinity receptors (the biological features of cytokines are summarized in Table 1).

Keywords

Multiple Sclerosis Amyotrophic Lateral Sclerosis Viral Meningitis British Biotech Rial Meningitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA (1990) Cytokine accumulation in the CSF in multiple sclerosis patients: frequent detection of interleukin 1 and tumor necrosis factor but no interleukin 6. Neurology 40:1735–1739PubMedGoogle Scholar
  2. 2.
    Maimore D, Gregory S, Arnason BGW, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. 32:67–74Google Scholar
  3. 3.
    Peter JB, Boctor FN, Tourtellotte WW (1991) Serum and CSF of IL-2, sIL-2R, TNFα and IL-lβ in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 41:121–123PubMedGoogle Scholar
  4. 4.
    Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K (1991) Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 102:230–234CrossRefGoogle Scholar
  5. 5.
    Weller M, Stevens A, Sommer N, Melms A, Dichgans J, Wiethölter H (1991) Comparative analysis of cytokine pattern in immunological, infectious, and oncological neurological diseases. J Neurol Sci 104:215–221PubMedCrossRefGoogle Scholar
  6. 6.
    Gallo P, Argentiero V, Piccinno MG, Giometto B, Pagni S, Bozza F, Tavolato B (1989)Google Scholar
  7. Soluble mediators of the immune response in cerbrospinal fluid and serum of patients with multiple sclerosis. In: Battaglia MA (ed) Multiple Sclerosis Research. Elsevier SP, pp 61–70Google Scholar
  8. 7.
    Frei K, Leist TP, Maeger A, Gallo P, Leppert D, Zinkernagel RM, Fontana A (1988) Production of B cell stimulatory factor-2 and interferon in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model of infection and in patients. J Exp Med 168:449–453PubMedCrossRefGoogle Scholar
  9. 8.
    Houssiau FA, Bukasa K, Sindic CJM, van Damme JV, van Snick JV (1988) Elevated levels of the 26 K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol 71:320–323PubMedGoogle Scholar
  10. 9.
    Leppert D, Frei K, Gallo P, Yasargil MG, Hess K, Baumgartner G, Fontana A (1989) Brain tumors: detection of B-cell stimulatory factor-2/interleukin 6 in the absence of oligoclonal bands of immunoglobulins. J Neuroimmunol 24:259–264PubMedCrossRefGoogle Scholar
  11. 10.
    Gallo P, Frei K, Leppert D, Fontana A (1990) On the intrathecal synthesis of immunoglobulins: detection of BSF-2/IL-6 in CSF. In: Marrosu MG, Cianchetti C, Tavola-to B (eds) Trends in Neuroimmunology. Plenum Press, New York, pp 33–39CrossRefGoogle Scholar
  12. 11.
    Paemen L, Olsson T, Söderström M, van Damme J, Opdenakkern G (1994) Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis, and other inflammatory neurological diseases. Eur J Neurol 1:55–63CrossRefGoogle Scholar
  13. 12.
    Frei K, Fredrikson S, Fontana A, Link H (1991) Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 312:147–153Google Scholar
  14. 13.
    Leist EP, Frei K, Kam-Hansen S, Zinkernagel R, Fontana A (1988) Tumor necrosis factor a in cerebrospinal fluid during bacterial but not viral meningitis. J Exp Med 167:1734–1748Google Scholar
  15. 14.
    Gallo P, Piccinno MG, Krzalic L, Tavolato B (1989) Tumor necrosis factor alpha (TNFα) and neurological diseases. Failure in detecting TNFa) in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumors. J Neuroimmunol 23:41–44PubMedCrossRefGoogle Scholar
  16. 15.
    Franciotta DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Citterio A, Melzi d’Eril GV (1989) Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 26:787–789PubMedCrossRefGoogle Scholar
  17. 16.
    Sharief MK, Noori MA, Ciardi M, Cirelli A, Thompson EJ (1993) Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNFa and blood-brain barrier damage. J Neuroimmunol 325:467–472Google Scholar
  18. 17.
    Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. New Engl J Med 325:467–472PubMedCrossRefGoogle Scholar
  19. 18.
    Gallo P, Piccinno MG, Pagni S, Tavolato B (1988) Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 24:795–797PubMedCrossRefGoogle Scholar
  20. 19.
    Adachi K, Kumamoto T, Araki S (1989) Interleukin-2 receptor levels indicating relapse in multiple sclerosis (Letter). Lancet i:559–560CrossRefGoogle Scholar
  21. 20.
    Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometto B, Bozza F, Tavolato B (1989) Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and IFNy in serum and cerebrospinal fluid. J Neurol Sci 92:9–15PubMedCrossRefGoogle Scholar
  22. 21.
    Adachi K, Kumamoto T, Araki S (1990) Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neurol 28:687–691PubMedCrossRefGoogle Scholar
  23. 22.
    Trotter JL, van der Veen RC, Clifford DB (1990) Serial studies of interleukin-2 in chronic progressive multiple sclerosis: occurence of “bursts” and effect of cyclosporine. J Neuroimmunol 28:9–14PubMedCrossRefGoogle Scholar
  24. 23.
    Gallo P, Piccinno MG, Tavolato B, Sidén Ä (1991) A longitudinal study on IL-2, sIL-2R, IL-4 and IFNγ in multiple sclerosis CSF and serum. J Neurol Sci 101:227–232PubMedCrossRefGoogle Scholar
  25. 24.
    Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV (1991) Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopatho-genesis. Ann Neurol 30:48–53PubMedCrossRefGoogle Scholar
  26. 25.
    Trotter JL, Collins KG, van der Veen RC (1991) Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-α levels. J Neuroimmunol 33: 29–36PubMedCrossRefGoogle Scholar
  27. 26.
    Sharief MK, Hentges R, Thompson EJ (1991) The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis. J Neuroimmunol 32:43–51PubMedCrossRefGoogle Scholar
  28. 27.
    Ott M, Demisch L, Engelhardt W, Fisher PA (1993) Interleukin-2, soluble interleukin-2 receptor, neopterin, L-tryptophan, and β2microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J Neurol 241:108–114PubMedCrossRefGoogle Scholar
  29. 28.
    Sharief MK, Thompson EJ (1993) Correlation of interleukin-2 and soluble interleukin-2 receptors with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry 56:169–174PubMedCrossRefGoogle Scholar
  30. 29.
    Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL (1988) Elevated levels of soluble interleukin-2 receptors in multiple sclerosis (letter). N Engl J Med 319:1206Google Scholar
  31. 30.
    Capra R, Mattioli F, Marciano N, Vignolo LA, Bettinzioli M, Airò P, Cattaneo R (1990) Significantly higher levels of soluble interleukin-2 in patients with relapsing-remitting multiple sclerosis compared to healthy subjects (lettere). Arch Neurol 47:254PubMedCrossRefGoogle Scholar
  32. 31.
    Hartung HP, Hughes RAC, Taylor WA, Heininger K, Reiners K, Toyka KVT (1990) T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of IL-2 receptors. Neurology 40:215–218PubMedGoogle Scholar
  33. 32.
    Kittur SD, Kittur DS, Soncrant TT, Rapoport SI, Tourtellotte WW, Nagel JL, Adler WH (1990) Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann Neurol 28:169–173CrossRefGoogle Scholar
  34. 33.
    Bansil S, Troiano R, Cook SD, Rohowsky-Kochan C (1991) Serum soluble interleukin-2 receptor levels in chronic progressive, stable, and steroid treated multiple sclerosis. Acta Neurol Scand 84:282–285PubMedCrossRefGoogle Scholar
  35. 34.
    Fesenmeier JT, Whitaker JN, Herman PK, Walker DP (1991) Cerebrospinal fluid levels of myelin basic protein-like material and soluble interleukin-2 receptor in multiple sclerosis. J Neuroimmunol 34:77–80PubMedCrossRefGoogle Scholar
  36. 35.
    Chalon MP, Sindic CJM, Laterre EC (1993) Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. Acta Neurol Scand 87:77–82PubMedCrossRefGoogle Scholar
  37. 36.
    Sharief MK, Hentges R, Ciardi M, Thompson EJ (1993) In vivo relationship of interleukin-2 and soluble interleukin-2 receptor with clinical activity in multiple sclerosis. J Neurol 240:46–50PubMedCrossRefGoogle Scholar
  38. 37.
    Link J, Söderström M, Olsson T, Höjeberg B, Ljungdahl Á, Gustafsson A, Link H. Increased TGFβ, IL-4 and IFNγ in multiple sclerosis. Ann Neurol 36:379–386Google Scholar
  39. 38.
    Rieckmann P, Albrecht BA, Kitze B, Weber T, Tumani H, Broocks A, Luer W, Helwig A, Poser S (1995) Tumor necrosis factor-a messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37:82–88PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • P. Gallo
    • 1
  • B. Tavolato
    • 1
  1. 1.Institute of Neurology, II Neurologic ClinicUniversity of PaduaPaduaItaly

Personalised recommendations